Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.

The US Centers for Medicare and Medicaid Services (CMS) created a new billing code to help diagnose coronavirus in its beneficiaries on 5 March, as well as fact sheets on medical care and transport of COVID-19 patients, but patients who get their health care through low-cost insurance plans may not be able to afford the testing, said a House Committee chairman.

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.